Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2009-4-16
pubmed:databankReference
pubmed:abstractText
High-frequency microsatellite-instable (MSI-H) tumors account for approximately 15% of colorectal cancers. Therapeutic decisions for colorectal cancer are empirically based and currently do not emphasize molecular subclassification despite an increasing collection of gene expression information. Our objective was to identify low molecular weight compounds with preferential activity against MSI colorectal cancers using combined gene expression data sets.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/17-(allylamino)-17-demethoxygeldanam..., http://linkedlifedata.com/resource/pubmed/chemical/2-(4-morpholinyl)-8-phenyl-4H-1-benz..., http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzoquinones, http://linkedlifedata.com/resource/pubmed/chemical/Chromones, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Hydroxamic Acids, http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Lactams, Macrocyclic, http://linkedlifedata.com/resource/pubmed/chemical/Morpholines, http://linkedlifedata.com/resource/pubmed/chemical/Phosphatidylinositol 3-Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt, http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus, http://linkedlifedata.com/resource/pubmed/chemical/trichostatin A
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2829-39
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:19351759-Algorithms, pubmed-meshheading:19351759-Antineoplastic Agents, pubmed-meshheading:19351759-Benzoquinones, pubmed-meshheading:19351759-Cell Cycle, pubmed-meshheading:19351759-Cell Line, Tumor, pubmed-meshheading:19351759-Chromones, pubmed-meshheading:19351759-Colorectal Neoplasms, pubmed-meshheading:19351759-Computational Biology, pubmed-meshheading:19351759-DNA Mismatch Repair, pubmed-meshheading:19351759-Drug Evaluation, Preclinical, pubmed-meshheading:19351759-Enzyme Inhibitors, pubmed-meshheading:19351759-Gene Expression Profiling, pubmed-meshheading:19351759-Humans, pubmed-meshheading:19351759-Hydroxamic Acids, pubmed-meshheading:19351759-Immunosuppressive Agents, pubmed-meshheading:19351759-Lactams, Macrocyclic, pubmed-meshheading:19351759-Microsatellite Instability, pubmed-meshheading:19351759-Morpholines, pubmed-meshheading:19351759-Phosphatidylinositol 3-Kinases, pubmed-meshheading:19351759-Proto-Oncogene Proteins c-akt, pubmed-meshheading:19351759-Sirolimus
pubmed:year
2009
pubmed:articleTitle
Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway.
pubmed:affiliation
Department of Internal Medicine, The University of Michigan Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural